Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18328212 | 0.82 | MAPT (0.41) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL25855372 | 0.81 | TDP1 (0.41) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL1282757 | 0.81 | TSHR (0.45) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL5198511 | 0.81 | CASP1 (0.49) | CASP1 | |
| SCHEMBL8781902 | 0.79 | TDP1 (0.42) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL2006527 | 0.79 | TDP1 (0.42) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL8302678 | 0.79 | TSHR (0.37) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL17553504 | 0.79 | MAPT (0.42) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL10885419 | 0.79 | TDP1 (0.39) | TDP1MAPTCACNA1BAPBA1CASP1 | |
| SCHEMBL6401374 | 0.78 | CASP1 (0.41) | TDP1CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | TDP1 4765/4885MAPT 3990/4885CACNA1B 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.